Podcast: Teva Seeks Label Change for Azilect
Jan 02, 2012•6 min
Listen to this episode in Metacast mobile app
Don't just listen to podcasts. Learn from them with transcripts, summaries, and chapters for every episode. Skim, search, and bookmark insights. Learn more
Episode description
This fall, The FDA recommended that Teva Neuroscience’s drug rasagiline, brand name Azilect, should not be granted status “to slow the clinical progression of PD.”
Mentioned in this episode:
The Foundation’s landmark research study is exploring the connection between sense of smell and brain disease. People with and without Parkinson's can help by taking a free scratch-and-sniff test. Get yours at mysmelltest.org/request.
For the best experience, listen in Metacast app for iOS or Android